

Sponsor

Novartis

Generic Drug Name

Secukinumab

Therapeutic Area of Trial

Moderate to severe plaque psoriasis

Approved Indication

Investigational

Protocol Number

CAIN457A2307

Title

A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in patients with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab

Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)

Study Phase

Phase III

Study Start/End Dates

02-Dec-2011 to 24-Apr-2013

Study Design/Methodology

Randomized, double-blind, double-dummy, parallel group comparison of secukinumab 10 mg/kg intravenous (i.v.) versus secukinumab 300 mg subcutaneous (s.c.) over 8 weeks

(i.v. period) followed by a 32-week open label Maintenance period of secukinumab 300 mg s.c. treatment every 4 weeks and an 8-week treatment-free Follow-up period.

Centers

23 centers worldwide: Austria (1), Canada (2), Germany (5), France (1), India (3), Japan (4), Slovakia (1), and USA (6).

Publication

No publications.

Objectives

Primary Objective

The primary objective was to evaluate the efficacy of i.v. administration of secukinumab compared with s.c. administration of secukinumab with respect to both Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment (IGA) 0 or 1 response (co-primary endpoints) at Week 8 in study CAIN457A2307 in moderate to severe chronic plaque-type psoriasis in patients who achieved a partial response after 12 weeks of treatment in study CAIN457A2304.

Secondary objectives

- To assess the efficacy of a higher dose of secukinumab than administered in CAIN457A2304 in achieving PASI 75 or IGA mod 2011 0 or 1 response over time, up to Week 40
- To assess the efficacy of secukinumab treatment regimens with respect to PASI 50/75/90/100 response and IGA mod 2011 0 or 1 response over time, up to Week 40
- To assess the efficacy of secukinumab treatment regimens with respect to PASI score and IGA mod 2011 score over time, up to Week 40
- To assess the clinical safety and tolerability of secukinumab treatment regimens as assessed by vital signs, clinical laboratory variables, electrocardiograms (ECGs), and adverse events (AEs) monitoring
- To investigate the effects of secukinumab treatment regimens with respect to the Dermatology Life Quality Index (DLQI) 0 or 1 achievement at Week 8, and over time, up to Week 40
- To investigate the effects of secukinumab treatment regimens with respect to changes in DLQI at Week 8, and over time, up to Week 40
- To assess the effects of secukinumab treatment regimens with respect to EuroQOL-5D (EQ-5D) score at Week 8, and over time, up to Week 40
- To investigate the development of immunogenicity against secukinumab
- To investigate the relationship between response to secukinumab treatment and having failed to respond to previous biologic psoriasis therapy

Test Product (s), Dose(s), and Mode(s) of Administration

Secukinumab 150 mg was provided in the form of a lyophilisate cake in a glass vial. Patients randomized to either i.v. administration (10 mg/kg) or s.c. administration (300 mg).

Statistical Methods

The randomized set consisted of all patients who were randomized at visit 1, which was identical to the Full Analysis Set (FAS), both sets included 43 patients. Patients were analyzed according to the treatment assigned to at randomization. The Safety set included all patients who took at least one dose of study drug. All efficacy analyses were based on the FAS and all safety analyses were based on the Safety set.

Patient disposition, protocol deviations, demographic data, baseline characteristics, relevant medical histories, comorbid medical conditions, and exposure to study drug were summarized by treatment group. Concomitant medications and significant non-drug therapies were coded by the ATC classification, and MedDRA version 16.0 was used to code medical history/co-existing disease and AEs/SAEs.

The co-primary efficacy variables were PASI 75 response and the IGA mod 2011 0 or 1 response evaluated at Week 8. The co-primary efficacy variables were compared by Cochran-Mantel-Haenszel (CMH) test stratified by previous treatment group in study CAIN457A2304 and presented with risk difference estimates, 95% confidence intervals, and two-sided p-values for comparisons between dose groups.

Summary statistics by treatment group were provided for absolute PASI score, PASI 50, PASI 75, PASI 90, PASI 100, and IGA mod 2011 0 or 1 responses at each visit up to week 8 and over time, comparing i.v. versus s.c. dose groups by stratified CMH test and a logistic regression model with treatment group, treatment group in CAIN457A2304, and baseline PASI score as effects. Summary statistics were shown for the health state assessment (EQ-5D) and DLQI by visit and treatment group.

All AEs and SAEs were summarized overall and by treatment received. Potential compound-specific routine safety risks (infections and infestations, malignancy, administration and immune reactions, major adverse cardiovascular events, Crohn's disease exacerbation, hepatotoxicity, and QTc prolongation) were presented by treatment group for standardized MedDRA query (SMQ) and Novartis MedDRA Query (NMQ), along with all lower level terms.

Laboratory data were summarized by treatment group and CTCAE shift tables. Vital signs were summarized with descriptive statistics for changes from baseline for each post-baseline visit. Patients with clinically notable abnormalities were summarized. Listings of immunogenicity data and PK data were provided.

Study Population: Inclusion/Exclusion Criteria and Demographics**Key inclusion criteria:**

1. Adults, male or female, aged at least 18 years of age.
2. Patients who participated in study CAIN457A2304 and had achieved a partial response after 12 weeks of treatment with no major protocol deviations. A partial response was defined as having achieved a PASI 50 response, but not a PASI 75 response.

Exclusion criteria:

1. Forms of psoriasis other than chronic plaque-type (*e.g.*, pustular, erythrodermic and guttate psoriasis). Ongoing use of prohibited psoriasis treatments (*e.g.*, topical or systemic corticosteroids, UV therapy).
2. Patients with the following conditions were excluded:
 - Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception, suspected by a positive urine test and confirmed by a positive serum beta human chorionic gonadotropin (β -hCG) test, and until the termination of gestation.
 - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment. Effective contraception includes barrier method, total abstinence, female or male partner sterilization, and use of established methods of contraception (full details are provided in the study protocol).
 - Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy.
 - Emergence of a condition (including but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the Investigator significantly immunocompromised the patient and/or placed the patient at unacceptable risk for receiving immunomodulatory therapy.
 - Significant medical problems, including but not limited to the following: uncontrolled hypertension (systolic ≥ 160 mmHg and / or diastolic ≥ 95 mmHg); congestive heart failure (New York Heart Association status of class III or IV); or other unstable cardiovascular conditions (*e.g.*, myocardial infarction since randomization to study CAIN457A2304).
 - Current severe progressive or uncontrolled disease or any medical or psychiatric condition including ongoing alcohol or drug abuse, which, in the Investigator's opinion, could have precluded the patient from participating in the study.
 - Active systemic infections during the last two weeks (exception: common cold) prior to randomization or any infection that reoccurred on a regular basis.
 - Infection with HIV, hepatitis B, hepatitis C

- Latent tuberculosis established before randomization in study CAIN457A2304 and for whom treatment was either NOT initiated before randomization or NOT maintained in that study according to local country guidelines.
 - Treated patient in study CAIN457A2304 whose latent tuberculosis was found to have progressed to active tuberculosis.
 - Inability or unwillingness to have undergone repeated venipuncture (*e.g.*, because of poor tolerability or lack of access to veins)
3. Patients exposed to the following therapies were excluded:
- Use of investigational drugs other than secukinumab since randomization in study CAIN457A2304.
 - Ongoing use of other non-psoriasis prohibited treatments.
 - Patients not willing to limit UV light exposure (*e.g.*, sunbathing and/or the use of tanning devices) during the course of the study.
 - Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304.
 - Live vaccination planned during the study period.

No additional exclusions were applied by the Investigator in order to ensure that the study population was representative of all eligible patients.

Participant Flow

Patient disposition – Entire treatment period (Randomized set)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Disposition /Reason	n (%)	n (%)	n (%)	n (%)
Randomized	15	6	14	8
Completed treatment	14 (93.3)	5 (83.3)	11 (78.6)	6 (75.0)
Discontinued treatment	1 (6.7)	1 (16.7)	3 (21.4)	2 (25.0)
Entered follow-up	2 (13.3)	1 (16.7)	2 (14.3)	0
Completed follow-up	2 (13.3)	1 (16.7)	2 (14.3)	0

Patient disposition – i.v. period (Randomized set)

	AIN457 150 mg - AIN457 300 mg s.c. N=15*	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Disposition /Reason	n (%)	n (%)	n (%)	n (%)
Randomized	15	6	14	8
Completed I.V	14 (93.3)	6 (100.0)	14 (100.0)	6 (75.0)

	AIN457 150 mg - AIN457 300 mg s.c. N=15*	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Disposition /Reason	n (%)	n (%)	n (%)	n (%)
Discontinued prior to s.c. secukinumab treatment after CRF Visit Week 4	1 (6.7)	0 (0.0)	0 (0.0)	2 (25.0)
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22	Any AIN457 dose N=43
Disposition /Reason	n (%)	n (%)	n (%)
Randomized	21	22	43
Completed I.V	20 (95.2)	20 (90.9)	40 (93.0)
Discontinued prior to s.c. secukinumab treatment after CRF Visit Week 4	1 (4.8)	2 (9.1)	3 (7.0)
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)
Lost to follow-up	0 (0.0)	1 (4.5)	1 (2.3)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	1 (4.5)	1 (2.3)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (4.8)	0 (0.0)	1 (2.3)
Death	0 (0.0)	0 (0.0)	0 (0.0)

* Column headings refer to the following: patients who received 150 mg s.c. regimen in CAIN457A2304 and then were switched to either 300 mg s.c. or 10 mg/kg i.v. in study CAIN457A2307. Patients who received 300 mg s.c. in CAIN457A2304 and were switched to either 300 mg s.c. or 10 mg/kg i.v. in study CAIN457A2307.

Patient disposition – Entire treatment period (Randomized set)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Disposition /Reason	n (%)	n (%)	n (%)	n (%)
Randomized	15	6	14	8
Completed treatment	14 (93.3)	5 (83.3)	11 (78.6)	6 (75.0)
Discontinued treatment	1 (6.7)	1 (16.7)	3 (21.4)	2 (25.0)
Adverse event	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Lost to follow-up	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (6.7)	1 (16.7)	1 (7.1)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22	Any AIN457 dose N=43
Disposition /Reason	n (%)	n (%)	n (%)
Randomized	21	22	43
Completed treatment	19 (90.5)	17 (77.3)	36 (83.7)
Discontinued treatment	2 (9.5)	5 (22.7)	7 (16.3)
Adverse event	0 (0.0)	1 (4.5)	1 (2.3)
Lack of efficacy	0 (0.0)	1 (4.5)	1 (2.3)
Lost to follow-up	0 (0.0)	1 (4.5)	1 (2.3)
Non-compliance with study treatment	0 (0.0)	0 (0.0)	0 (0.0)
Physician decision	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	1 (4.5)	1 (2.3)
No longer requires treatment	0 (0.0)	0 (0.0)	0 (0.0)
Study terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)
Technical problems	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	2 (9.5)	1 (4.5)	3 (7.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)

Baseline Characteristics

Demographics and background characteristics - Entire treatment period (Randomized set)

Demographic variable	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22	Any AIN457 dose N=43
Age group in years, n(%)			
< 65	17 (81.0)	21 (95.5)	38 (88.4)
>= 65	4 (19.0)	1 (4.5)	5 (11.6)
Age (Years)			
n	21	22	43
Mean	47.6	45.7	46.6
SD	14.53	12.14	13.24
Median	46.0	48.0	48.0
Min - Max	27 - 71	20 - 65	20 - 71
Gender, n(%)			
Female	5 (23.8)	9 (40.9)	14 (32.6)
Male	16 (76.2)	13 (59.1)	29 (67.4)
Race, n(%)			
Caucasian	16 (76.2)	16 (72.7)	32 (74.4)
Black	0 (0.0)	1 (4.5)	1 (2.3)
Asian	5 (23.8)	4 (18.2)	9 (20.9)
Native American	0 (0.0)	1 (4.5)	1 (2.3)
Ethnicity, n(%)			
East Asian	3 (14.3)	2 (9.1)	5 (11.6)
South Asian	2 (9.5)	2 (9.1)	4 (9.3)
Other	9 (42.9)	12 (54.5)	21 (48.8)
Unknown	2 (9.5)	1 (4.5)	3 (7.0)
Not reported	5 (23.8)	5 (22.7)	10 (23.3)
Height (cm)			
n	21	22	43
Mean	172.96	175.49	174.26
SD	10.630	10.461	10.496
Median	171.40	176.65	173.99
Min - Max	157.5 - 194.2	155.0 - 194.0	155.0 - 194.2
Weight (kg)			
n	21	22	43
Mean	102.16	92.40	97.16
SD	28.402	22.644	25.785
Median	100.60	93.00	93.80
Min - Max	54.5 - 181.4	54.9 - 143.8	54.5 - 181.4
BMI (kg/m ²)			
n	21	22	43

Demographic variable	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22	Any AIN457 dose N=43
Mean	34.09	29.97	31.98
SD	8.859	6.649	7.989
Median	32.90	31.69	31.95
Min - Max	19.5 - 59.1	18.0 - 45.1	18.0 - 59.1
Current smoker at baseline, n (%)			
No	14 (66.7)	15 (68.2)	29 (67.4)
Yes	7 (33.3)	7 (31.8)	14 (32.6)

Outcome Measures

Summary of Efficacy

Primary outcome measures

Statistical analysis (Cochran-Mantel-Haenszel test) of IGA mod 2011 0 or 1, PASI 75 and PASI 90 response at Week 8 (non-responder imputation) (FAS)

Response criterion	Treatment comparison "test" vs. "control"	"test" n/m (%)	"control" n/m (%)	Confidence Interval (95% CI)	p-value
IGA 0/1	AIN457 10 mg /kg i.v. vs. AIN457 300 mg s.c.	14/ 21 (66.7)	7/ 21 (33.3)	(1.12, 14.76)	0.0332
PASI 75	AIN457 10 mg /kg i.v. vs. AIN457 300 mg s.c.	19/ 21 (90.5)	14/ 21 (66.7)	(0.86, 27.38)	0.0649
PASI 90	AIN457 10 mg /kg i.v. vs. AIN457 300 mg s.c.	13/ 21 (61.9)	2/ 21 (9.5)	(2.88, 101.09)	0.0005

n = number of patients with response, m = number of patients evaluable

Secondary outcome measures

Number (%) of patients with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response by visit (non-responder imputation) (FAS)

Visit	Criterion	AIN457 300 mg s.c. N=21		AIN457 10 mg /kg i.v. N=22	
		n/m	(%)	n/m	(%)
Week 2	IGA 0/1	2/21	(9.5)	2/21	(9.5)
	PASI 75	4/21	(19.0)	10/21	(47.6)
	PASI 50	18/21	(85.7)	21/21	(100.0)
	PASI 90	0/21	(0.0)	4/21	(19.0)
	PASI 100	0/21	(0.0)	0/21	(0.0)
Week 4	IGA 0/1	2/21	(9.5)	10/21	(47.6)
	PASI 75	7/21	(33.3)	16/21	(76.2)
	PASI 50	18/21	(85.7)	20/21	(95.2)
	PASI 90	1/21	(4.8)	6/21	(28.6)

Visit	Criterion	AIN457 300 mg s.c. N=21		AIN457 10 mg /kg i.v. N=22	
		n/m	(%)	n/m	(%)
Week 8	PASI 100	0/21	(0.0)	2/21	(9.5)
	IGA 0/1	7/21	(33.3)	14/21	(66.7)
	PASI 75	14/21	(66.7)	19/21	(90.5)
	PASI 50	19/21	(90.5)	20/21	(95.2)
	PASI 90	2/21	(9.5)	13/21	(61.9)
Week 12	PASI 100	0/21	(0.0)	3/21	(14.3)
	IGA 0/1	8/21	(38.1)	15/21	(71.4)
	PASI 75	13/21	(61.9)	18/21	(85.7)
	PASI 50	18/21	(85.7)	20/21	(95.2)
	PASI 90	4/21	(19.0)	14/21	(66.7)
Week 16	PASI 100	0/21	(0.0)	3/21	(14.3)
	IGA 0/1	6/21	(28.6)	14/21	(66.7)
	PASI 75	14/21	(66.7)	17/21	(81.0)
	PASI 50	18/21	(85.7)	18/21	(85.7)
	PASI 90	3/21	(14.3)	12/21	(57.1)
Week 20	PASI 100	0/21	(0.0)	4/21	(19.0)
	IGA 0/1	5/21	(23.8)	13/21	(61.9)
	PASI 75	14/21	(66.7)	17/21	(81.0)
	PASI 50	17/21	(81.0)	18/21	(85.7)
	PASI 90	3/21	(14.3)	12/21	(57.1)
Week 24	PASI 100	1/21	(4.8)	3/21	(14.3)
	IGA 0/1	5/21	(23.8)	10/21	(47.6)
	PASI 75	11/21	(52.4)	16/21	(76.2)
	PASI 50	17/21	(81.0)	18/21	(85.7)
	PASI 90	4/21	(19.0)	12/21	(57.1)
Week 28	PASI 100	2/21	(9.5)	3/21	(14.3)
	IGA 0/1	5/21	(23.8)	9/21	(42.9)
	PASI 75	13/21	(61.9)	13/21	(61.9)
	PASI 50	16/21	(76.2)	18/21	(85.7)
	PASI 90	5/21	(23.8)	8/21	(38.1)
Week 32	PASI 100	0/21	(0.0)	3/21	(14.3)
	IGA 0/1	3/21	(14.3)	9/21	(42.9)
	PASI 75	12/21	(57.1)	14/21	(66.7)
	PASI 50	16/21	(76.2)	17/21	(81.0)
	PASI 90	4/21	(19.0)	9/21	(42.9)
Week 36	PASI 100	0/21	(0.0)	2/21	(9.5)
	IGA 0/1	4/21	(19.0)	11/21	(52.4)
	PASI 75	12/21	(57.1)	13/21	(61.9)
	PASI 50	17/21	(81.0)	16/21	(76.2)
	PASI 90	5/21	(23.8)	10/21	(47.6)
	PASI 100	0/21	(0.0)	2/21	(9.5)

Visit	Criterion	AIN457 300 mg s.c. N=21		AIN457 10 mg /kg i.v. N=22	
		n/m	(%)	n/m	(%)
Week 40	IGA 0/1	6/21	(28.6)	9/21	(42.9)
	PASI 75	10/21	(47.6)	13/21	(61.9)
	PASI 50	18/21	(85.7)	15/21	(71.4)
	PASI 90	5/21	(23.8)	10/21	(47.6)
	PASI 100	0/21	(0.0)	3/21	(14.3)

Summary statistics for PASI score and change from baseline by visit (LOCF)-entire treatment period

		AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Baseline	n	21				22			
	Mean	22.052				21.500			
	SD	8.8380				9.9114			
	Min	13.40				12.30			
	Q1	15.400				15.400			
	Median	19.100				17.850			
	Q3	27.600				24.300			
	Max	48.40				50.80			
Week 2	n	21	21	21	21	21	21	21	21
	Mean	22.052	7.490	-14.562	-65.427	21.810	5.467	-16.343	-74.824
	SD	8.8380	3.8473	7.3992	14.1732	10.0466	3.4059	7.7506	10.6180
	Min	13.40	3.00	-39.10	-81.91	12.30	1.20	-39.60	-93.42
	Q1	15.400	4.300	-16.600	-74.627	15.500	3.500	-20.200	-77.953
	Median	19.100	6.700	-12.700	-70.652	18.200	5.200	-12.200	-74.394
	Q3	27.600	9.300	-10.000	-58.095	24.300	6.400	-11.300	-65.854
	Max	48.40	16.80	-4.30	-27.56	50.80	15.20	-8.10	-58.79
Week 4	n	21	21	21	21	21	21	21	21
	Mean	22.052	6.814	-15.238	-69.804	21.810	3.495	-18.314	-83.063
	SD	8.8380	4.3966	6.3589	14.4443	10.0466	2.3874	9.3159	10.7849

		AIN457 150 mg - AIN457 10 mg/kg i.v. N=14				AIN457 300 mg - AIN457 10 mg/kg i.v. N=8			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Baseline	n	14				8			
	Mean	23.579				17.863			
	SD	11.7957				3.5420			
	Min	12.30				15.00			
	Q1	15.500				15.400			
	Median	18.550				17.250			
	Q3	27.900				18.300			
	Max	50.80				26.00			
Week 2	n	14	14	14	14	7	7	7	7
	Mean	23.579	6.129	-17.450	-73.704	18.271	4.143	-14.129	-77.065
	SD	11.7957	3.8917	9.1091	11.5032	3.6160	1.6692	3.4466	8.9623
	Min	12.30	1.20	-39.60	-93.42	15.40	1.80	-20.20	-90.22
	Q1	15.500	3.900	-22.700	-77.953	15.400	2.500	-16.600	-86.264
	Median	18.550	5.550	-14.650	-74.294	17.500	4.000	-11.900	-77.273
	Q3	27.900	7.500	-10.300	-65.753	18.400	5.800	-11.400	-69.412
	Max	50.80	15.20	-8.10	-58.79	26.00	6.20	-11.30	-64.57
Week 4	n	14	14	14	14	7	7	7	7
	Mean	23.579	3.721	-19.857	-82.823	18.271	3.043	-15.229	-83.543
	SD	11.7957	2.7624	11.0515	12.7660	3.6160	1.4513	2.8277	5.8485

		AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Baseline	n	21				22			
	Mean	22.052				21.500			
	SD	8.8380				9.9114			
	Min	13.40				12.30			
	Q1	15.400				15.400			
	Median	19.100				17.850			
	Q3	27.600				24.300			
	Max	48.40				50.80			
Week 2	n	21	21	21	21	21	21	21	21
	Mean	22.052	7.490	-14.562	-65.427	21.810	5.467	-16.343	-74.824
	SD	8.8380	3.8473	7.3992	14.1732	10.0466	3.4059	7.7506	10.6180
	Min	13.40	3.00	-39.10	-81.91	12.30	1.20	-39.60	-93.42
	Q1	15.400	4.300	-16.600	-74.627	15.500	3.500	-20.200	-77.953
	Median	19.100	6.700	-12.700	-70.652	18.200	5.200	-12.200	-74.394
	Q3	27.600	9.300	-10.000	-58.095	24.300	6.400	-11.300	-65.854
	Max	48.40	16.80	-4.30	-27.56	50.80	15.20	-8.10	-58.79
Week 4	n	21	21	21	21	21	21	21	21
	Mean	22.052	6.814	-15.238	-69.804	21.810	3.495	-18.314	-83.063
	SD	8.8380	4.3966	6.3589	14.4443	10.0466	2.3874	9.3159	10.7849
		AIN457 150 mg - AIN457 300 mg s.c. N=15				AIN457 300 mg - AIN457 300 mg s.c. N=6			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 4	Min	13.80	0.90	-32.30	-94.44	13.40	3.70	-26.30	-87.67
	Q1	15.400	3.000	-16.700	-83.333	14.500	4.900	-22.500	-81.522
	Median	18.800	4.200	-15.100	-72.727	23.200	5.350	-14.200	-63.606
	Q3	29.000	11.000	-10.900	-59.429	27.600	8.800	-8.900	-61.379
	Max	48.40	16.10	-6.30	-40.38	30.00	9.20	-8.50	-58.10
Week 8	n	15	15	15	15	6	6	6	6
	Mean	22.080	6.027	-16.053	-74.878	21.983	4.900	-17.083	-76.783
	SD	9.7249	5.0675	6.2382	15.7461	6.9011	3.4537	7.1340	14.6169
	Min	13.80	0.40	-31.10	-97.40	13.40	2.10	-26.80	-89.33
	Q1	15.400	2.200	-20.800	-85.106	14.500	3.200	-24.300	-88.043
	Median	18.800	3.600	-15.300	-76.712	23.200	3.550	-15.500	-83.117
	Q3	29.000	8.400	-11.200	-64.256	27.600	5.400	-11.300	-62.759
	Max	48.40	17.30	-8.10	-41.18	30.00	11.60	-9.10	-54.33
Week 12	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.220	-16.860	-77.213	21.983	6.067	-15.917	-73.058
	SD	9.7249	4.1709	7.6406	14.9453	6.9011	5.6270	7.2970	22.9941
	Min	13.80	0.40	-37.20	-97.40	13.40	0.30	-27.50	-97.76
	Q1	15.400	2.100	-20.800	-89.005	14.500	2.500	-20.400	-91.667
	Median	18.800	4.200	-15.000	-78.261	23.200	5.000	-15.050	-77.433
	Q3	29.000	6.300	-10.800	-71.429	27.600	7.200	-9.000	-58.621

		AIN457 150 mg - AIN457 10 mg/kg i.v. N=14				AIN457 300 mg - AIN457 10 mg/kg i.v. N=8			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 4	Min	12.30	0.00	-47.60	-100.00	15.40	1.20	-20.20	-93.48
	Q1	15.500	1.600	-24.300	-93.701	15.400	2.100	-17.200	-87.647
	Median	18.550	3.300	-16.950	-82.409	17.500	3.000	-14.900	-80.519
	Q3	27.900	6.600	-11.600	-74.194	18.400	3.600	-12.400	-79.221
	Max	50.80	8.40	-8.00	-62.64	26.00	5.80	-12.20	-77.69
Week 8	n	14	14	14	14	7	7	7	7
	Mean	23.579	1.921	-21.657	-91.324	18.271	1.914	-16.357	-90.291
	SD	11.7957	2.9208	11.8179	11.1147	3.6160	1.7668	2.2648	6.2811
	Min	12.30	0.00	-50.00	-100.00	15.40	0.40	-20.20	-97.71
	Q1	15.500	0.200	-24.300	-98.942	15.400	1.200	-17.200	-93.478
	Median	18.550	0.800	-16.150	-95.303	17.500	1.500	-17.000	-91.176
	Q3	27.900	2.700	-13.400	-87.879	18.400	1.700	-13.800	-88.961
	Max	50.80	11.20	-11.60	-59.86	26.00	5.80	-13.70	-77.69
Week 12	n	14	14	14	14	7	7	7	7
	Mean	23.579	2.429	-21.150	-88.466	18.271	1.600	-16.671	-92.330
	SD	11.7957	3.0024	12.1339	12.5875	3.6160	1.9732	1.9448	7.5651
	Min	12.30	0.00	-50.00	-100.00	15.40	0.00	-20.20	-100.00
	Q1	15.500	0.800	-22.500	-97.305	15.400	0.000	-17.500	-100.000
	Median	18.550	1.800	-16.150	-91.358	17.500	1.200	-16.400	-93.478
	Q3	27.900	2.000	-12.800	-87.578	18.400	1.800	-15.400	-90.110
		AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 4	Min	13.40	0.90	-32.30	-94.44	12.30	0.00	-47.60	-100.00
	Q1	15.400	3.700	-16.700	-81.595	15.500	2.100	-20.700	-90.947
	Median	19.100	5.100	-15.100	-70.690	18.200	3.200	-15.600	-82.210
	Q3	27.600	9.200	-10.900	-61.379	24.300	5.000	-12.200	-78.065
	Max	48.40	16.10	-6.30	-40.38	50.80	8.40	-8.00	-62.64
Week 8	n	21	21	21	21	21	21	21	21
	Mean	22.052	5.705	-16.348	-75.422	21.810	1.919	-19.890	-90.980
	SD	8.8380	4.6075	6.3397	15.0913	10.0466	2.5459	9.9435	9.6116
	Min	13.40	0.40	-31.10	-97.40	12.30	0.00	-50.00	-100.00
	Q1	15.400	2.800	-20.800	-85.106	15.500	0.600	-20.200	-97.844
	Median	19.100	3.600	-15.300	-81.379	18.200	1.200	-16.700	-93.407
	Q3	27.600	7.500	-11.300	-64.256	24.300	1.700	-13.800	-88.961
	Max	48.40	17.30	-8.10	-41.18	50.80	11.20	-11.60	-59.86
Week 12	n	21	21	21	21	21	21	21	21
	Mean	22.052	5.462	-16.590	-76.026	21.810	2.152	-19.657	-89.754
	SD	8.8380	4.4996	7.3734	17.0949	10.0466	2.6810	10.0755	11.1194
	Min	13.40	0.30	-37.20	-97.76	12.30	0.00	-50.00	-100.00
	Q1	15.400	2.500	-20.400	-89.005	15.500	0.800	-20.200	-97.305
	Median	19.100	4.200	-15.000	-78.261	18.200	1.600	-16.400	-92.593
	Q3	27.600	6.300	-10.800	-71.429	24.300	2.000	-14.100	-87.671

		AIN457 150 mg - AIN457 300 mg s.c.				AIN457 300 mg - AIN457 300 mg s.c.			
		N=15				N=6			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 12	Max	48.40	14.20	-8.40	-41.18	30.00	16.40	-8.50	-35.43
Week 16	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.580	-16.500	-75.161	21.983	5.300	-16.683	-74.874
	SD	9.7249	4.5135	8.3488	18.1298	6.9011	5.3292	8.3103	21.5593
	Min	13.80	0.80	-39.30	-94.81	13.40	0.80	-29.20	-97.33
	Q1	15.400	2.400	-20.800	-88.356	14.500	2.000	-23.700	-85.870
	Median	18.800	4.500	-14.600	-79.592	23.200	3.800	-14.350	-83.728
	Q3	29.000	9.100	-12.900	-60.656	27.600	5.800	-9.800	-60.000
	Max	48.40	15.20	-5.20	-25.49	30.00	15.60	-8.70	-38.58
Week 20	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.593	-16.487	-74.977	21.983	5.367	-16.617	-73.286
	SD	9.7249	4.7485	8.7811	19.8870	6.9011	4.9690	8.8026	23.9859
	Min	13.80	0.80	-41.10	-94.81	13.40	0.00	-30.00	-100.00
	Q1	15.400	2.600	-20.800	-84.615	14.500	1.700	-23.400	-87.313
	Median	18.800	4.500	-14.600	-79.755	23.200	4.150	-14.350	-82.629
	Q3	29.000	7.200	-12.000	-70.492	27.600	8.600	-11.700	-46.457
	Max	48.40	18.10	-2.30	-11.27	30.00	13.60	-5.90	-40.69
Week 24	n	15	15	15	15	6	6	6	6

		AIN457 150 mg - AIN457 10 mg/kg i.v.				AIN457 300 mg - AIN457 10 mg/kg i.v.			
		N=14				N=8			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 12	Max	50.80	11.20	-10.30	-59.86	26.00	5.80	-14.00	-77.69
Week 16	n	14	14	14	14	7	7	7	7
	Mean	23.579	2.507	-21.071	-88.681	18.271	1.714	-16.557	-91.572
	SD	11.7957	3.4720	11.9765	15.7146	3.6160	1.9659	2.1570	7.8226
	Min	12.30	0.00	-49.20	-100.00	15.40	0.00	-20.20	-100.00
	Q1	15.500	0.600	-23.600	-96.850	15.400	0.000	-17.500	-100.000
	Median	18.550	1.500	-16.150	-95.077	17.500	1.200	-17.000	-93.407
	Q3	27.900	2.500	-12.800	-87.879	18.400	2.000	-15.200	-87.013
	Max	50.80	11.20	-8.50	-46.70	26.00	5.80	-13.40	-77.69
Week 20	n	14	14	14	14	7	7	7	7
	Mean	23.579	3.450	-20.129	-84.328	18.271	1.671	-16.600	-91.793
	SD	11.7957	4.5681	12.1411	23.1846	3.6160	1.8997	2.1174	7.0116
	Min	12.30	0.00	-47.80	-100.00	15.40	0.00	-20.20	-100.00
	Q1	15.500	0.600	-21.700	-96.129	15.400	0.800	-17.500	-95.604
	Median	18.550	2.400	-16.150	-90.872	17.500	1.200	-17.200	-93.478
	Q3	27.900	3.000	-12.800	-87.671	18.400	1.800	-14.500	-89.412
	Max	50.80	16.10	-2.10	-11.54	26.00	5.80	-14.20	-77.69
Week 24	n	14	14	14	14	7	7	7	7

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 12	Max	48.40	16.40	-8.40	-35.43	50.80	11.20	-10.30	-59.86
Week 16	n	21	21	21	21	21	21	21	21
	Mean	22.052	5.500	-16.552	-75.079	21.810	2.243	-19.567	-89.645
	SD	8.8380	4.6235	8.1280	18.6092	10.0466	3.0235	9.9692	13.4471
	Min	13.40	0.80	-39.30	-97.33	12.30	0.00	-49.20	-100.00
	Q1	15.400	2.400	-20.800	-85.870	15.500	0.600	-20.200	-96.850
	Median	19.100	3.900	-14.600	-81.198	18.200	1.400	-16.700	-93.478
	Q3	27.600	5.800	-11.700	-60.656	24.300	2.000	-14.900	-87.879
	Max	48.40	15.60	-5.20	-25.49	50.80	11.20	-8.50	-46.70
Week 20	n	21	21	21	21	21	21	21	21
	Mean	22.052	5.529	-16.524	-74.494	21.810	2.857	-18.952	-86.816
	SD	8.8380	4.6869	8.5645	20.5253	10.0466	3.9223	10.0032	19.4202
	Min	13.40	0.00	-41.10	-100.00	12.30	0.00	-47.80	-100.00
	Q1	15.400	2.600	-20.800	-84.783	15.500	0.800	-20.200	-95.604
	Median	19.100	4.400	-14.600	-80.476	18.200	1.800	-16.700	-92.208
	Q3	27.600	7.200	-11.800	-70.492	24.300	2.900	-14.500	-88.889
	Max	48.40	18.10	-2.30	-11.27	50.80	16.10	-2.10	-11.54
Week 24	n	21	21	21	21	21	21	21	21

Visit	Statistic	AIN457 150 mg - AIN457 300 mg s.c. N=15				AIN457 300 mg - AIN457 300 mg s.c. N=6			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 24	Mean	22.080	5.840	-16.240	-73.643	21.983	6.050	-15.933	-70.353
	SD	9.7249	4.9574	8.9204	21.5822	6.9011	5.8739	9.1951	26.3645
	Min	13.80	0.00	-40.60	-100.00	13.40	0.00	-30.00	-100.00
	Q1	15.400	3.700	-20.800	-86.780	14.500	1.800	-23.500	-86.567
	Median	18.800	4.600	-14.600	-76.440	23.200	4.750	-13.600	-79.715
	Q3	29.000	7.800	-11.100	-65.217	27.600	8.600	-9.000	-40.690
	Max	48.40	18.70	-1.70	-8.33	30.00	16.40	-5.90	-35.43
Week 28	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.773	-16.307	-73.230	21.983	6.383	-15.600	-69.909
	SD	9.7249	4.7843	9.0757	21.9938	6.9011	6.5844	9.0322	28.9249
	Min	13.80	0.80	-40.20	-94.81	13.40	0.80	-29.20	-97.33
	Q1	15.400	2.200	-20.800	-87.037	14.500	0.800	-22.300	-94.030
	Median	18.800	4.900	-14.100	-78.205	23.200	4.850	-14.600	-79.922
	Q3	29.000	8.200	-12.200	-71.429	27.600	8.600	-7.000	-40.690
	Max	48.40	17.90	-2.50	-12.25	30.00	18.40	-5.90	-27.56
Week 32	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.667	-16.413	-74.488	21.983	7.200	-14.783	-64.973
	SD	9.7249	4.8074	8.8441	21.5000	6.9011	6.1787	9.2634	26.3911
	Min	13.80	0.40	-41.20	-97.26	13.40	0.80	-29.20	-97.33
	Q1	15.400	2.200	-20.800	-86.503	14.500	3.000	-22.600	-81.884

		AIN457 150 mg - AIN457 10 mg/kg i.v. N=14				AIN457 300 mg - AIN457 10 mg/kg i.v. N=8			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 24	Mean	23.579	4.393	-19.186	-82.759	18.271	1.686	-16.586	-91.891
	SD	11.7957	5.5200	10.0627	23.5714	3.6160	1.9004	1.8352	7.0432
	Min	12.30	0.00	-37.90	-100.00	15.40	0.00	-20.20	-100.00
	Q1	15.500	0.600	-23.200	-96.129	15.400	0.600	-17.200	-96.104
	Median	18.550	1.700	-16.250	-91.338	17.500	1.200	-16.300	-93.407
	Q3	27.900	5.600	-14.000	-80.247	18.400	1.800	-15.200	-89.412
	Max	50.80	16.10	-2.10	-11.54	26.00	5.80	-14.80	-77.69
Week 28	n	14	14	14	14	7	7	7	7
	Mean	23.579	5.314	-18.264	-79.451	18.271	2.614	-15.657	-86.013
	SD	11.7957	6.4741	9.3946	25.4899	3.6160	1.6708	2.7951	7.2530
	Min	12.30	0.00	-37.00	-100.00	15.40	1.20	-20.20	-93.48
	Q1	15.500	0.600	-24.300	-96.129	15.400	1.500	-17.200	-91.429
	Median	18.550	2.800	-16.050	-87.341	17.500	1.800	-16.000	-88.312
	Q3	27.900	10.600	-13.700	-71.429	18.400	3.900	-13.600	-77.692
	Max	50.80	18.50	-0.80	-4.40	26.00	5.80	-11.50	-74.68
Week 32	n	14	14	14	14	7	7	7	7
	Mean	23.579	6.536	-17.043	-75.640	18.271	2.371	-15.900	-87.390
	SD	11.7957	8.9974	9.2215	32.1496	3.6160	2.2126	3.0914	11.4365
	Min	12.30	0.00	-36.50	-100.00	15.40	0.30	-20.20	-98.29
	Q1	15.500	0.800	-20.800	-94.521	15.400	0.600	-17.200	-96.104
		AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 24	Mean	22.052	5.900	-16.152	-72.703	21.810	3.490	-18.319	-85.803
	SD	8.8380	5.0831	8.7670	22.4086	10.0466	4.7538	8.2708	19.8869
	Min	13.40	0.00	-40.60	-100.00	12.30	0.00	-37.90	-100.00
	Q1	15.400	3.700	-20.800	-86.567	15.500	0.600	-19.500	-96.104
	Median	19.100	4.600	-14.600	-76.440	18.200	1.200	-16.300	-93.143
	Q3	27.600	7.800	-11.100	-65.217	24.300	4.800	-14.900	-82.114
	Max	48.40	18.70	-1.70	-8.33	50.80	16.10	-2.10	-11.54
Week 28	n	21	21	21	21	21	21	21	21
	Mean	22.052	5.948	-16.105	-72.281	21.810	4.624	-17.186	-80.487
	SD	8.8380	5.1904	8.8408	23.4549	10.0466	6.0347	8.3379	25.7435
	Min	13.40	0.80	-40.20	-97.33	12.30	0.00	-37.00	-100.00
	Q1	15.400	2.200	-20.800	-87.037	15.500	1.200	-20.200	-93.478
	Median	19.100	4.900	-14.100	-79.048	18.200	2.400	-16.000	-88.312
	Q3	27.600	8.200	-12.200	-71.429	24.300	4.300	-13.700	-74.675
	Max	48.40	18.40	-2.50	-12.25	50.80	21.80	3.60	19.78
Week 32	n	21	21	21	21	21	21	21	21
	Mean	22.052	6.105	-15.948	-71.770	21.810	5.148	-16.662	-79.557
	SD	8.8380	5.1211	8.7621	22.7398	10.0466	7.6246	7.6450	27.2634
	Min	13.40	0.40	-41.20	-97.33	12.30	0.00	-36.50	-100.00
	Q1	15.400	2.400	-20.800	-85.124	15.500	0.800	-18.900	-94.521

		AIN457 150 mg - AIN457 300 mg s.c. N=15				AIN457 300 mg - AIN457 300 mg s.c. N=6			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 32	Median	18.800	4.900	-14.200	-81.695	23.200	6.200	-12.000	-71.187
	Q3	29.000	7.800	-13.200	-63.115	27.600	8.600	-7.000	-40.690
	Max	48.40	17.00	-3.40	-16.67	30.00	18.40	-5.90	-27.56
Week 36	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.660	-16.420	-75.046	21.983	7.350	-14.633	-64.915
	SD	9.7249	4.7399	8.3063	19.9446	6.9011	5.9113	8.6391	25.3179
	Min	13.80	0.40	-39.20	-97.26	13.40	2.40	-27.60	-92.00
	Q1	15.400	1.000	-20.800	-93.506	14.500	2.600	-22.100	-80.597
	Median	18.800	5.100	-14.400	-79.487	23.200	6.050	-12.600	-74.322
	Q3	29.000	9.000	-12.400	-63.115	27.600	8.600	-7.000	-40.690
	Max	48.40	16.10	-4.30	-21.08	30.00	18.40	-5.90	-27.56
Week 40	n	15	15	15	15	6	6	6	6
	Mean	22.080	5.240	-16.840	-78.755	21.983	8.250	-13.733	-60.935
	SD	9.7249	4.9429	6.1165	13.7464	6.9011	5.5806	7.9824	23.1089
	Min	13.80	0.40	-31.00	-97.40	13.40	3.90	-24.40	-81.33
	Q1	15.400	0.900	-20.800	-94.444	14.500	5.600	-22.000	-79.710
	Median	18.800	5.000	-15.000	-79.487	23.200	6.100	-11.950	-69.733
	Q3	29.000	7.200	-13.200	-64.706	27.600	8.600	-6.200	-40.690
	Max	48.40	17.40	-8.70	-59.43	30.00	19.20	-5.90	-24.41
		AIN457 150 mg - AIN457 10 mg/kg i.v. N=14				AIN457 300 mg - AIN457 10 mg/kg i.v. N=8			
Visit	Statistic	Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 32	Median	18.550	2.700	-16.050	-88.507	17.500	1.200	-17.000	-93.407
	Q3	27.900	8.400	-13.800	-72.358	18.400	5.100	-14.600	-77.692
	Max	50.80	30.00	3.60	19.78	26.00	5.80	-10.30	-66.88
Week 36	n	14	14	14	14	7	7	7	7
	Mean	23.579	6.757	-16.821	-75.109	18.271	2.314	-15.957	-87.770
	SD	11.7957	9.0523	8.9676	32.1354	3.6160	2.1169	2.9506	10.5139
	Min	12.30	0.00	-36.60	-100.00	15.40	0.30	-20.20	-98.29
	Q1	15.500	0.800	-20.800	-94.521	15.400	0.600	-17.200	-96.104
	Median	18.550	2.700	-16.050	-89.372	17.500	1.200	-17.000	-93.407
	Q3	27.900	10.700	-13.800	-71.159	18.400	4.600	-14.500	-77.692
	Max	50.80	30.00	3.60	19.78	26.00	5.80	-10.80	-70.13
Week 40	n	14	14	14	14	7	7	7	7
	Mean	23.579	7.500	-16.079	-71.899	18.271	2.214	-16.057	-88.450
	SD	11.7957	9.4399	8.7785	33.4159	3.6160	2.0186	2.7275	9.2924
	Min	12.30	0.00	-36.30	-100.00	15.40	0.00	-20.20	-100.00
	Q1	15.500	0.800	-20.100	-94.521	15.400	0.600	-17.500	-96.104
	Median	18.550	3.600	-15.700	-88.978	17.500	1.400	-16.800	-92.308
	Q3	27.900	11.400	-13.800	-54.987	18.400	3.600	-14.100	-77.692
	Max	50.80	30.70	3.60	19.78	26.00	5.80	-11.80	-76.62

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 32	Median	19.100	5.000	-14.100	-79.592	18.200	2.000	-16.500	-88.636
	Q3	27.600	7.800	-11.700	-63.115	24.300	5.600	-14.600	-76.955
	Max	48.40	18.40	-3.40	-16.67	50.80	30.00	3.60	19.78
Week 36	n	21	21	21	21	21	21	21	21
	Mean	22.052	6.143	-15.910	-72.151	21.810	5.276	-16.533	-79.329
	SD	8.8380	5.0075	8.2243	21.4637	10.0466	7.6951	7.4201	27.2362
	Min	13.40	0.40	-39.20	-97.26	12.30	0.00	-36.60	-100.00
	Q1	15.400	2.600	-20.800	-85.763	15.500	0.800	-18.900	-94.521
	Median	19.100	5.400	-14.400	-79.487	18.200	2.400	-16.500	-90.123
	Q3	27.600	8.600	-11.500	-63.115	24.300	5.800	-14.500	-72.840
	Max	48.40	18.40	-4.30	-21.08	50.80	30.00	3.60	19.78
Week 40	n	21	21	21	21	21	21	21	21
	Mean	22.052	6.100	-15.952	-73.663	21.810	5.738	-16.071	-77.416
	SD	8.8380	5.1798	6.6472	18.2709	10.0466	8.1033	7.2334	28.5592
	Min	13.40	0.40	-31.00	-97.40	12.30	0.00	-36.30	-100.00
	Q1	15.400	3.000	-20.800	-82.759	15.500	0.800	-18.900	-94.521
	Median	19.100	5.100	-14.400	-73.298	18.200	2.200	-16.500	-90.062
	Q3	27.600	7.200	-12.400	-64.706	24.300	6.400	-14.100	-72.840
	Max	48.40	19.20	-5.90	-24.41	50.80	30.70	3.60	19.78

Base = Baseline, Post = Post baseline, Abs. change = Post - Base, Perc. change = 100 x Abs. change / Base.
For each post-baseline visit only subjects with a value at both baseline and the respective post-baseline visit are included.

Number (%) of subjects in each IGA mod 2011 category by visit (LOCF)-entire treatment period

Visit	IGA mod 2011 category	AIN457 150mg- 300mg s.c. N=15			AIN457 300mg- 300mg s.c. N=6		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 2	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	0/ 15	(0.0)	(0.0, 25.3)	2/ 6	(33.3)	(6.0, 75.9)
	mild	11/ 15	(73.3)	(44.8, 91.1)	1/ 6	(16.7)	(0.9, 63.5)
	moderate	4/ 15	(26.7)	(8.9, 55.2)	3/ 6	(50.0)	(13.9, 86.1)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 4	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	1/ 15	(6.7)	(0.3, 34.0)	1/ 6	(16.7)	(0.9, 63.5)
	mild	10/ 15	(66.7)	(38.7, 87.0)	3/ 6	(50.0)	(13.9, 86.1)
	moderate	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 8	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	5/ 15	(33.3)	(13.0, 61.3)	2/ 6	(33.3)	(6.0, 75.9)
	mild	6/ 15	(40.0)	(17.5, 67.1)	2/ 6	(33.3)	(6.0, 75.9)
	moderate	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 12	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	6/ 15	(40.0)	(17.5, 67.1)	2/ 6	(33.3)	(6.0, 75.9)
	mild	4/ 15	(26.7)	(8.9, 55.2)	3/ 6	(50.0)	(13.9, 86.1)
	moderate	5/ 15	(33.3)	(13.0, 61.3)	1/ 6	(16.7)	(0.9, 63.5)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)

Visit	IGA mod 2011 category	AIN457 150mg- 10mg/kg i.v. N=14			AIN457 300mg- 10mg/kg i.v. N=8		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 2	clear	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
	almost clear	1/ 14	(7.1)	(0.4, 35.8)	1/ 7	(14.3)	(0.8, 58.0)
	mild	8/ 14	(57.1)	(29.6, 81.2)	6/ 7	(85.7)	(42.0, 99.2)
	moderate	5/ 14	(35.7)	(14.0, 64.4)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 4	clear	2/ 14	(14.3)	(2.5, 43.8)	0/ 7	(0.0)	(0.0, 43.9)
	almost clear	4/ 14	(28.6)	(9.6, 58.0)	4/ 7	(57.1)	(20.2, 88.2)
	mild	7/ 14	(50.0)	(24.0, 76.0)	3/ 7	(42.9)	(11.8, 79.8)
	moderate	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 8	clear	3/ 14	(21.4)	(5.7, 51.2)	1/ 7	(14.3)	(0.8, 58.0)
	almost clear	7/ 14	(50.0)	(24.0, 76.0)	3/ 7	(42.9)	(11.8, 79.8)
	mild	2/ 14	(14.3)	(2.5, 43.8)	3/ 7	(42.9)	(11.8, 79.8)
	moderate	2/ 14	(14.3)	(2.5, 43.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 12	clear	1/ 14	(7.1)	(0.4, 35.8)	2/ 7	(28.6)	(5.1, 69.7)
	almost clear	8/ 14	(57.1)	(29.6, 81.2)	4/ 7	(57.1)	(20.2, 88.2)
	mild	3/ 14	(21.4)	(5.7, 51.2)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	2/ 14	(14.3)	(2.5, 43.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Visit	IGA mod 2011 category	AIN457 300 mg s.c. N=21			AIN457 10 mg /kg i.v. N=22		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 2	clear	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
	almost clear	2/ 21	(9.5)	(1.7, 31.8)	2/ 21	(9.5)	(1.7, 31.8)
	mild	12/ 21	(57.1)	(34.4, 77.4)	14/ 21	(66.7)	(43.1, 84.5)
	moderate	7/ 21	(33.3)	(15.5, 56.9)	5/ 21	(23.8)	(9.1, 47.5)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
Week 4	clear	0/ 21	(0.0)	(0.0, 19.2)	2/ 21	(9.5)	(1.7, 31.8)
	almost clear	2/ 21	(9.5)	(1.7, 31.8)	8/ 21	(38.1)	(19.0, 61.3)
	mild	13/ 21	(61.9)	(38.7, 81.0)	10/ 21	(47.6)	(26.4, 69.7)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	1/ 21	(4.8)	(0.2, 25.9)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
Week 8	clear	0/ 21	(0.0)	(0.0, 19.2)	4/ 21	(19.0)	(6.3, 42.6)
	almost clear	7/ 21	(33.3)	(15.5, 56.9)	10/ 21	(47.6)	(26.4, 69.7)
	mild	8/ 21	(38.1)	(19.0, 61.3)	5/ 21	(23.8)	(9.1, 47.5)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	2/ 21	(9.5)	(1.7, 31.8)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
Week 12	clear	0/ 21	(0.0)	(0.0, 19.2)	3/ 21	(14.3)	(3.8, 37.4)
	almost clear	8/ 21	(38.1)	(19.0, 61.3)	12/ 21	(57.1)	(34.4, 77.4)
	mild	7/ 21	(33.3)	(15.5, 56.9)	4/ 21	(19.0)	(6.3, 42.6)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	2/ 21	(9.5)	(1.7, 31.8)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)

Visit	IGA mod 2011 category	AIN457 150mg- 300mg s.c. N=15			AIN457 300mg- 300mg s.c. N=6		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 16	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	mild	6/ 15	(40.0)	(17.5, 67.1)	3/ 6	(50.0)	(13.9, 86.1)
	moderate	5/ 15	(33.3)	(13.0, 61.3)	1/ 6	(16.7)	(0.9, 63.5)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 20	clear	0/ 15	(0.0)	(0.0, 25.3)	1/ 6	(16.7)	(0.9, 63.5)
	almost clear	3/ 15	(20.0)	(5.3, 48.6)	1/ 6	(16.7)	(0.9, 63.5)
	mild	8/ 15	(53.3)	(27.4, 77.7)	2/ 6	(33.3)	(6.0, 75.9)
	moderate	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 24	clear	1/ 15	(6.7)	(0.3, 34.0)	1/ 6	(16.7)	(0.9, 63.5)
	almost clear	2/ 15	(13.3)	(2.3, 41.6)	1/ 6	(16.7)	(0.9, 63.5)
	mild	6/ 15	(40.0)	(17.5, 67.1)	1/ 6	(16.7)	(0.9, 63.5)
	moderate	6/ 15	(40.0)	(17.5, 67.1)	3/ 6	(50.0)	(13.9, 86.1)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 28	clear	1/ 15	(6.7)	(0.3, 34.0)	1/ 6	(16.7)	(0.9, 63.5)
	almost clear	2/ 15	(13.3)	(2.3, 41.6)	1/ 6	(16.7)	(0.9, 63.5)
	mild	8/ 15	(53.3)	(27.4, 77.7)	2/ 6	(33.3)	(6.0, 75.9)
	moderate	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)

Visit	IGA mod 2011 category	AIN457 150mg- 10mg/kg i.v. N=14			AIN457 300mg- 10mg/kg i.v. N=8		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 16	clear	2/ 14	(14.3)	(2.5, 43.8)	2/ 7	(28.6)	(5.1, 69.7)
	almost clear	7/ 14	(50.0)	(24.0, 76.0)	4/ 7	(57.1)	(20.2, 88.2)
	mild	3/ 14	(21.4)	(5.7, 51.2)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	2/ 14	(14.3)	(2.5, 43.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 20	clear	2/ 14	(14.3)	(2.5, 43.8)	1/ 7	(14.3)	(0.8, 58.0)
	almost clear	6/ 14	(42.9)	(18.8, 70.4)	5/ 7	(71.4)	(30.3, 94.9)
	mild	4/ 14	(28.6)	(9.6, 58.0)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	2/ 14	(14.3)	(2.5, 43.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 24	clear	2/ 14	(14.3)	(2.5, 43.8)	1/ 7	(14.3)	(0.8, 58.0)
	almost clear	3/ 14	(21.4)	(5.7, 51.2)	5/ 7	(71.4)	(30.3, 94.9)
	mild	5/ 14	(35.7)	(14.0, 64.4)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	3/ 14	(21.4)	(5.7, 51.2)	0/ 7	(0.0)	(0.0, 43.9)
	severe	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 28	clear	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
	almost clear	5/ 14	(35.7)	(14.0, 64.4)	4/ 7	(57.1)	(20.2, 88.2)
	mild	3/ 14	(21.4)	(5.7, 51.2)	3/ 7	(42.9)	(11.8, 79.8)
	moderate	5/ 14	(35.7)	(14.0, 64.4)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)

Visit	IGA mod 2011 category	AIN457 300 mg s.c. N=21			AIN457 10 mg /kg i.v. N=22		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 16	clear	0/ 21	(0.0)	(0.0, 19.2)	4/ 21	(19.0)	(6.3, 42.6)
	almost clear	6/ 21	(28.6)	(12.2, 52.3)	11/ 21	(52.4)	(30.3, 73.6)
	mild	9/ 21	(42.9)	(22.6, 65.6)	4/ 21	(19.0)	(6.3, 42.6)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	2/ 21	(9.5)	(1.7, 31.8)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
Week 20	clear	1/ 21	(4.8)	(0.2, 25.9)	3/ 21	(14.3)	(3.8, 37.4)
	almost clear	4/ 21	(19.0)	(6.3, 42.6)	11/ 21	(52.4)	(30.3, 73.6)
	mild	10/ 21	(47.6)	(26.4, 69.7)	5/ 21	(23.8)	(9.1, 47.5)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	2/ 21	(9.5)	(1.7, 31.8)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)
Week 24	clear	2/ 21	(9.5)	(1.7, 31.8)	3/ 21	(14.3)	(3.8, 37.4)
	almost clear	3/ 21	(14.3)	(3.8, 37.4)	8/ 21	(38.1)	(19.0, 61.3)
	mild	7/ 21	(33.3)	(15.5, 56.9)	6/ 21	(28.6)	(12.2, 52.3)
	moderate	9/ 21	(42.9)	(22.6, 65.6)	3/ 21	(14.3)	(3.8, 37.4)
	severe	0/ 21	(0.0)	(0.0, 19.2)	1/ 21	(4.8)	(0.2, 25.9)
Week 28	clear	2/ 21	(9.5)	(1.7, 31.8)	1/ 21	(4.8)	(0.2, 25.9)
	almost clear	3/ 21	(14.3)	(3.8, 37.4)	9/ 21	(42.9)	(22.6, 65.6)
	mild	10/ 21	(47.6)	(26.4, 69.7)	6/ 21	(28.6)	(12.2, 52.3)
	moderate	6/ 21	(28.6)	(12.2, 52.3)	5/ 21	(23.8)	(9.1, 47.5)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)

Visit	IGA mod 2011 category	AIN457 150mg- 300mg s.c. N=15			AIN457 300mg- 300mg s.c. N=6		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 32	clear	1/ 15	(6.7)	(0.3, 34.0)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	1/ 15	(6.7)	(0.3, 34.0)	1/ 6	(16.7)	(0.9, 63.5)
	mild	8/ 15	(53.3)	(27.4, 77.7)	2/ 6	(33.3)	(6.0, 75.9)
	moderate	5/ 15	(33.3)	(13.0, 61.3)	3/ 6	(50.0)	(13.9, 86.1)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 36	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	2/ 15	(13.3)	(2.3, 41.6)	2/ 6	(33.3)	(6.0, 75.9)
	mild	8/ 15	(53.3)	(27.4, 77.7)	1/ 6	(16.7)	(0.9, 63.5)
	moderate	5/ 15	(33.3)	(13.0, 61.3)	3/ 6	(50.0)	(13.9, 86.1)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
Week 40	clear	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
	almost clear	4/ 15	(26.7)	(8.9, 55.2)	2/ 6	(33.3)	(6.0, 75.9)
	mild	6/ 15	(40.0)	(17.5, 67.1)	1/ 6	(16.7)	(0.9, 63.5)
	moderate	5/ 15	(33.3)	(13.0, 61.3)	3/ 6	(50.0)	(13.9, 86.1)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)
best category up to Week 40	clear	1/ 15	(6.7)	(0.3, 34.0)	1/ 6	(16.7)	(0.9, 63.5)
	almost clear	7/ 15	(46.7)	(22.3, 72.6)	1/ 6	(16.7)	(0.9, 63.5)
	mild	4/ 15	(26.7)	(8.9, 55.2)	3/ 6	(50.0)	(13.9, 86.1)
	moderate	3/ 15	(20.0)	(5.3, 48.6)	1/ 6	(16.7)	(0.9, 63.5)
	severe	0/ 15	(0.0)	(0.0, 25.3)	0/ 6	(0.0)	(0.0, 48.3)

Visit	IGA mod 2011 category	AIN457 150mg- 10mg/kg i.v. N=14			AIN457 300mg- 10mg/kg i.v. N=8		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 32	clear	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
	almost clear	4/ 14	(28.6)	(9.6, 58.0)	5/ 7	(71.4)	(30.3, 94.9)
	mild	4/ 14	(28.6)	(9.6, 58.0)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	4/ 14	(28.6)	(9.6, 58.0)	1/ 7	(14.3)	(0.8, 58.0)
	severe	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 36	clear	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
	almost clear	5/ 14	(35.7)	(14.0, 64.4)	6/ 7	(85.7)	(42.0, 99.2)
	mild	3/ 14	(21.4)	(5.7, 51.2)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	4/ 14	(28.6)	(9.6, 58.0)	0/ 7	(0.0)	(0.0, 43.9)
	severe	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
Week 40	clear	2/ 14	(14.3)	(2.5, 43.8)	1/ 7	(14.3)	(0.8, 58.0)
	almost clear	4/ 14	(28.6)	(9.6, 58.0)	3/ 7	(42.9)	(11.8, 79.8)
	mild	2/ 14	(14.3)	(2.5, 43.8)	3/ 7	(42.9)	(11.8, 79.8)
	moderate	5/ 14	(35.7)	(14.0, 64.4)	0/ 7	(0.0)	(0.0, 43.9)
	severe	1/ 14	(7.1)	(0.4, 35.8)	0/ 7	(0.0)	(0.0, 43.9)
best category up to Week 40	clear	5/ 14	(35.7)	(14.0, 64.4)	3/ 7	(42.9)	(11.8, 79.8)
	almost clear	6/ 14	(42.9)	(18.8, 70.4)	3/ 7	(42.9)	(11.8, 79.8)
	mild	3/ 14	(21.4)	(5.7, 51.2)	1/ 7	(14.3)	(0.8, 58.0)
	moderate	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)
	severe	0/ 14	(0.0)	(0.0, 26.8)	0/ 7	(0.0)	(0.0, 43.9)

Visit	IGA mod 2011 category	AIN457 300 mg s.c. N=21			AIN457 10 mg /kg i.v. N=22		
		n/m	(%)	95% CI	n/m	(%)	95% CI
Week 32	clear	1/ 21	(4.8)	(0.2, 25.9)	1/ 21	(4.8)	(0.2, 25.9)
	almost clear	2/ 21	(9.5)	(1.7, 31.8)	9/ 21	(42.9)	(22.6, 65.6)
	mild	10/ 21	(47.6)	(26.4, 69.7)	5/ 21	(23.8)	(9.1, 47.5)
	moderate	8/ 21	(38.1)	(19.0, 61.3)	5/ 21	(23.8)	(9.1, 47.5)
	severe	0/ 21	(0.0)	(0.0, 19.2)	1/ 21	(4.8)	(0.2, 25.9)
Week 36	clear	0/ 21	(0.0)	(0.0, 19.2)	1/ 21	(4.8)	(0.2, 25.9)
	almost clear	4/ 21	(19.0)	(6.3, 42.6)	11/ 21	(52.4)	(30.3, 73.6)
	mild	9/ 21	(42.9)	(22.6, 65.6)	4/ 21	(19.0)	(6.3, 42.6)
	moderate	8/ 21	(38.1)	(19.0, 61.3)	4/ 21	(19.0)	(6.3, 42.6)
	severe	0/ 21	(0.0)	(0.0, 19.2)	1/ 21	(4.8)	(0.2, 25.9)
Week 40	clear	0/ 21	(0.0)	(0.0, 19.2)	3/ 21	(14.3)	(3.8, 37.4)
	almost clear	6/ 21	(28.6)	(12.2, 52.3)	7/ 21	(33.3)	(15.5, 56.9)
	mild	7/ 21	(33.3)	(15.5, 56.9)	5/ 21	(23.8)	(9.1, 47.5)
	moderate	8/ 21	(38.1)	(19.0, 61.3)	5/ 21	(23.8)	(9.1, 47.5)
	severe	0/ 21	(0.0)	(0.0, 19.2)	1/ 21	(4.8)	(0.2, 25.9)
best category up to Week 40	clear	2/ 21	(9.5)	(1.7, 31.8)	8/ 21	(38.1)	(19.0, 61.3)
	almost clear	8/ 21	(38.1)	(19.0, 61.3)	9/ 21	(42.9)	(22.6, 65.6)
	mild	7/ 21	(33.3)	(15.5, 56.9)	4/ 21	(19.0)	(6.3, 42.6)
	moderate	4/ 21	(19.0)	(6.3, 42.6)	0/ 21	(0.0)	(0.0, 19.2)
	severe	0/ 21	(0.0)	(0.0, 19.2)	0/ 21	(0.0)	(0.0, 19.2)

Number (%) of subjects with Dermatology Life Quality Index response (DLQI 0 or 1) by visit (LOCF)- entire treatment period

Visit	Treatment	n/m (%)
Baseline	AIN457 150 mg - AIN457 300 mg s.c.	0/ 15 (0.0)
	AIN457 300 mg - AIN457 300 mg s.c.	0/ 6 (0.0)
	AIN457 150 mg - AIN457 10 mg/kg i.v	0/ 14 (0.0)
	AIN457 300 mg - AIN457 10 mg/kg i.v	1/ 7 (14.3)
	AIN457 300 mg s.c.	0/ 21 (0.0)
	AIN457 10 mg /kg i.v.	1/ 21 (4.8)
Week 8	AIN457 150 mg - AIN457 300 mg s.c.	4/ 14 (28.6)
	AIN457 300 mg - AIN457 300 mg s.c.	1/ 6 (16.7)
	AIN457 150 mg - AIN457 10 mg/kg i.v	9/ 14 (64.3)
	AIN457 300 mg - AIN457 10 mg/kg i.v	6/ 6 (100.0)
	AIN457 300 mg s.c.	5/ 20 (25.0)
	AIN457 10 mg /kg i.v.	15/ 20 (75.0)
Week 16	AIN457 150 mg - AIN457 300 mg s.c.	6/ 14 (42.9)
	AIN457 300 mg - AIN457 300 mg s.c.	2/ 6 (33.3)
	AIN457 150 mg - AIN457 10 mg/kg i.v	8/ 14 (57.1)
	AIN457 300 mg - AIN457 10 mg/kg i.v	6/ 6 (100.0)
	AIN457 300 mg s.c.	8/ 20 (40.0)
	AIN457 10 mg /kg i.v.	14/ 20 (70.0)
Week 24	AIN457 150 mg - AIN457 300 mg s.c.	7/ 14 (50.0)
	AIN457 300 mg - AIN457 300 mg s.c.	1/ 6 (16.7)
	AIN457 150 mg - AIN457 10 mg/kg i.v	5/ 14 (35.7)
	AIN457 300 mg - AIN457 10 mg/kg i.v	6/ 6 (100.0)
	AIN457 300 mg s.c.	8/ 20 (40.0)
	AIN457 10 mg /kg i.v.	11/ 20 (55.0)
Week 32	AIN457 150 mg - AIN457 300 mg s.c.	7/ 14 (50.0)
Week 32	AIN457 300 mg - AIN457 300 mg s.c.	1/ 6 (16.7)
	AIN457 150 mg - AIN457 10 mg/kg i.v	6/ 14 (42.9)
	AIN457 300 mg - AIN457 10 mg/kg i.v	5/ 6 (83.3)
	AIN457 300 mg s.c.	8/ 20 (40.0)
	AIN457 10 mg /kg i.v.	11/ 20 (55.0)
Week 40	AIN457 150 mg - AIN457 300 mg s.c.	7/ 14 (50.0)
	AIN457 300 mg - AIN457 300 mg s.c.	1/ 6 (16.7)
	AIN457 150 mg - AIN457 10 mg/kg i.v	6/ 14 (42.9)
	AIN457 300 mg - AIN457 10 mg/kg i.v	5/ 6 (83.3)
	AIN457 300 mg s.c.	8/ 20 (40.0)
	AIN457 10 mg /kg i.v.	11/ 20 (55.0)

Summary statistics for Dermatology Life Quality Index, including change from baseline by score and visit (LOCF) - entire treatment period

Parameter: DLQI TOTAL SCORE

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Baseline	n	21				21			
	Mean	15.1				13.2			
	SD	6.94				8.26			
	Min	8				0			
	Q1	9.0				7.0			
	Median	14.0				12.0			
	Q3	21.0				19.0			
	Max	30				27			
Week 8	n	20	20	20	20	20	20	20	20
	Mean	14.7	5.1	-9.7	-67.1	13.5	2.3	-11.3	-82.4
	SD	6.81	5.79	5.91	28.35	8.35	4.77	7.81	31.13
	Min	8	0	-24	-100	0	0	-27	-100
	Q1	9.0	1.5	-12.0	-86.6	7.0	0.0	-16.5	-100.0
	Median	12.5	3.0	-8.0	-72.3	12.0	0.0	-9.0	-100.0
	Q3	19.5	6.0	-5.5	-43.8	21.0	2.0	-6.5	-76.7
	Max	30	24	-1	-11	27	16	0	0
Week 16	n	20	20	20	20	20	20	20	20
	Mean	14.7	4.5	-10.3	-68.7	13.5	3.5	-10.0	-74.8

Parameter: DLQI TOTAL SCORE

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 16	SD	6.81	4.93	6.77	32.34	8.35	6.52	8.38	42.19
	Min	8	0	-24	-100	0	0	-27	-100
	Q1	9.0	0.5	-15.0	-97.2	7.0	0.0	-14.5	-100.0
	Median	12.5	3.5	-9.0	-83.6	12.0	0.0	-9.0	-100.0
	Q3	19.5	6.5	-5.5	-38.8	21.0	3.0	-5.0	-64.5
	Max	30	18	-1	-10	27	20	6	43
Week 24	n	20	20	20	20	20	20	20	20
	Mean	14.7	5.1	-9.6	-66.9	13.5	5.3	-8.2	-63.2
	SD	6.81	5.67	5.89	29.27	8.35	7.94	7.75	42.65
	Min	8	0	-24	-100	0	0	-23	-100
	Q1	9.0	0.0	-12.0	-100.0	7.0	0.0	-10.5	-100.0
	Median	12.5	5.0	-8.5	-65.2	12.0	1.0	-7.5	-73.9
	Q3	19.5	8.0	-5.5	-43.8	21.0	6.0	-2.5	-32.5
	Max	30	23	-1	-11	27	24	6	43
Week 32	n	20	20	20	20	20	20	20	20
	Mean	14.7	5.2	-9.5	-65.4	13.5	6.2	-7.4	-58.1
	SD	6.81	6.03	6.57	34.64	8.35	8.41	8.39	53.40
	Min	8	0	-24	-100	0	0	-23	-100
	Q1	9.0	0.0	-12.0	-100.0	7.0	0.0	-11.5	-100.0

Parameter: DLQI TOTAL SCORE

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 32	Median	12.5	4.0	-8.0	-71.9	12.0	0.5	-6.5	-89.2
	Q3	19.5	8.5	-5.5	-42.6	21.0	15.0	-1.5	-7.0
	Max	30	24	1	10	27	24	6	50
Week 40	n	20	20	20	20	20	20	20	20
	Mean	14.7	4.2	-10.5	-74.2	13.5	6.9	-6.6	-53.8
	SD	6.81	5.20	5.66	24.25	8.35	9.12	8.41	56.21
	Min	8	0	-24	-100	0	0	-23	-100
	Q1	9.0	0.0	-12.0	-100.0	7.0	0.0	-11.0	-100.0
	Median	12.5	3.0	-8.5	-75.9	12.0	1.0	-5.0	-84.6
	Q3	19.5	6.0	-7.0	-55.6	21.0	15.0	-1.5	-7.0
	Max	30	21	-4	-30	27	24	9	75

Base = Baseline, Post = Post baseline, Abs. change = Post - Base, Perc. change = 100 x Abs. change / Base.
For each post-baseline visit only subjects with a value at both baseline and the respective post-baseline visit are included.

Summary statistics of the EQ-5D health state assessment (from 0 to 100) and change from baseline by visit (LOCF)- entire treatment period

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Baseline	n	21				22			
	Mean	52.1				57.0			
	SD	26.16				21.91			
	Min	10				19			
	Q1	30.0				39.0			
	Median	60.0				61.0			
	Q3	70.0				71.0			
	Max	100				90			
Week 8	n	20	20	20	20	20	20	20	20
	Mean	53.8	69.0	15.2	71.0	57.3	83.8	26.5	73.1
	SD	25.69	24.67	25.27	157.11	19.93	13.29	21.79	99.42
	Min	10	20	-40	-57	20	40	1	1
	Q1	30.5	49.5	-0.5	-0.5	44.5	79.0	7.0	12.0
	Median	60.0	75.5	10.0	18.5	61.0	87.0	22.0	34.6
	Q3	70.5	87.5	28.0	69.2	70.5	94.0	39.0	85.0
	Max	100	99	74	673	90	96	73	365
Week 16	n	20	20	20	20	20	20	20	20
	Mean	53.8	68.7	14.9	76.9	57.3	79.2	21.9	57.5
	SD	25.69	24.10	28.33	153.63	19.93	22.68	25.48	98.10
Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 16	Min	10	25	-45	-64	20	0	-25	-100
	Q1	30.5	45.0	0.0	0.0	44.5	74.5	6.0	8.2
	Median	60.0	73.5	11.0	22.3	61.0	85.0	21.5	33.9
	Q3	70.5	88.0	31.0	95.7	70.5	94.5	40.0	80.0
	Max	100	100	69	627	90	97	75	375
Week 24	n	20	20	20	20	20	20	20	20
	Mean	53.8	69.4	15.6	74.6	57.3	74.3	17.0	45.3
	SD	25.69	26.14	27.62	171.69	19.93	25.38	27.00	82.05
	Min	10	21	-36	-51	20	0	-49	-100
	Q1	30.5	45.5	0.0	0.0	44.5	70.0	3.0	3.7
	Median	60.0	74.5	11.0	33.0	61.0	79.0	20.5	33.0
	Q3	70.5	94.5	29.5	72.9	70.5	92.0	38.0	85.0
Week 32	Max	100	99	83	755	90	99	50	250
	n	20	20	20	20	20	20	20	20
	Mean	53.8	71.7	17.9	80.2	57.3	72.1	14.8	40.9
	SD	25.69	25.38	26.02	177.33	19.93	26.29	28.22	80.96
	Min	10	20	-32	-45	20	0	-49	-100
	Q1	30.5	47.5	1.5	4.5	44.5	67.0	-2.0	-2.5
	Median	60.0	79.0	10.5	24.2	61.0	79.0	20.0	31.3
Week 32	Q3	70.5	93.0	28.0	62.5	70.5	89.0	36.5	74.0

Visit	Statistic	AIN457 300 mg s.c. N=21				AIN457 10 mg /kg i.v. N=22			
		Base	Post	Abs. change	Perc. change	Base	Post	Abs. change	Perc. change
Week 32	Max	100	100	85	773	90	100	61	216
Week 40	n	20	20	20	20	20	20	20	20
	Mean	53.8	73.1	19.3	87.2	57.3	71.5	14.2	41.3
	SD	25.69	21.61	24.37	173.59	19.93	25.96	28.48	86.92
	Min	10	29	-32	-45	20	0	-49	-100
	Q1	30.5	57.5	7.5	9.5	44.5	65.0	-1.0	-0.9
	Median	60.0	76.5	16.0	27.6	61.0	79.5	15.0	22.5
	Q3	70.5	94.0	24.5	84.9	70.5	90.0	35.5	80.0
	Max	100	99	84	764	90	98	59	250

Base = Baseline, Post = Post baseline, Abs. change = Post - Base, Perc. change = 100 x Abs. change / Base.
For each post-baseline visit only subjects with a value at both baseline and the respective post-baseline visit are included.

Immunogenicity

A total of 40 patients were tested for ADAs. A total of 8 out of 110 serum samples were positive in the screening assay. None of the screened positive samples was confirmed positive for antibodies specifically binding to secukinumab in the confirmatory assay. Therefore, none of the 40 patients in this study have developed immunogenicity response to secukinumab.

Relationship between response to AIN457 and failed response to previous biologic psoriasis therapy

This outcome measure was not analyzed due to the small sample size of the study (43 participants).

Summary of Safety

Safety Results

Display of adverse events

i.v. period

Absolute and relative frequencies for treatment-emergent AEs by primary system organ class – i.v. period (Safety set)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Primary system organ class	n (%)	n (%)	n (%)	n (%)
- Any primary system organ class	7 (46.7)	4 (66.7)	5 (35.7)	5 (62.5)
Infections and infestations	3 (20.0)	3 (50.0)	3 (21.4)	4 (50.0)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Primary system organ class	n (%)	n (%)	n (%)	n (%)
Injury, poisoning and procedural complications	2 (13.3)	0 (0.0)	1 (7.1)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	2 (13.3)	0 (0.0)	0 (0.0)	0 (0.0)
Vascular disorders	2 (13.3)	0 (0.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Immune system disorders	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Skin and subcutaneous tissue disorders	1 (6.7)	0 (0.0)	3 (21.4)	1 (12.5)
General disorders and administration site conditions	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Musculoskeletal and connective tissue disorders	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Nervous system disorders	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)

	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22
Primary system organ class	n (%)	n (%)
- Any primary system organ class	11 (52.4)	10 (45.5)
Infections and infestations	6 (28.6)	7 (31.8)
Injury, poisoning and procedural complications	2 (9.5)	1 (4.5)
Respiratory, thoracic and mediastinal disorders	2 (9.5)	0 (0.0)
Vascular disorders	2 (9.5)	0 (0.0)
Gastrointestinal disorders	1 (4.8)	0 (0.0)
Immune system disorders	1 (4.8)	0 (0.0)
Metabolism and nutrition disorders	1 (4.8)	0 (0.0)
Skin and subcutaneous tissue disorders	1 (4.8)	4 (18.2)
General disorders and administration site conditions	0 (0.0)	1 (4.5)
Musculoskeletal and connective tissue disorders	0 (0.0)	1 (4.5)
Nervous system disorders	0 (0.0)	1 (4.5)

Primary system organ classes are sorted in descending order of frequency in secukinumab 300 mg s.c. group

Absolute and relative frequencies for most frequent (at least 7% in any treatment group) treatment emergent adverse events, by preferred term – i.v. period (Safety set)

	AIN457 150 mg - AIN457 300 mg S.C. N=15	AIN457 300 mg - AIN457 300 mg S.C. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Preferred term	n (%)	n (%)	n (%)	n (%)
-Any preferred term	7 (46.7)	4 (66.7)	5 (35.7)	5 (62.5)
Nasopharyngitis	2 (13.3)	1 (16.7)	1 (7.1)	1 (12.5)
Dehydration	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Diarrhoea	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Gingivitis ulcerative	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Herpes zoster	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Pharyngitis	0 (0.0)	1 (16.7)	1 (7.1)	0 (0.0)
Back pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Ear infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Ecchymosis	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Fall	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Folliculitis	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Headache	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Injection site pain	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Intertrigo	0 (0.0)	0 (0.0)	1 (7.1)	1 (12.5)
Pruritus generalised	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Sinusitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	1 (7.1)	1 (12.5)

	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22
Preferred term	n (%)	n (%)
-Any preferred term	11 (52.4)	10 (45.5)
Nasopharyngitis	3 (14.3)	2 (9.1)
Dehydration	1 (4.8)	0 (0.0)
Diarrhoea	1 (4.8)	0 (0.0)
Gingivitis ulcerative	1 (4.8)	0 (0.0)
Herpes zoster	1 (4.8)	0 (0.0)
Pharyngitis	1 (4.8)	1 (4.5)
Back pain	0 (0.0)	1 (4.5)
Ear infection	0 (0.0)	1 (4.5)
Ecchymosis	0 (0.0)	1 (4.5)
Fall	0 (0.0)	1 (4.5)
Folliculitis	0 (0.0)	1 (4.5)
Headache	0 (0.0)	1 (4.5)
Injection site pain	0 (0.0)	1 (4.5)

Preferred term	AIN457 300 mg s.c. N=21 n (%)	AIN457 10 mg /kg i.v. N=22 n (%)
Intertrigo	0 (0.0)	2 (9.1)
Pruritus generalised	0 (0.0)	1 (4.5)
Sinusitis	0 (0.0)	1 (4.5)
Upper respiratory tract infection	0 (0.0)	2 (9.1)

Primary system organ classes are sorted in descending order of frequency in secukinumab 300 mg s.c. group

Entire treatment period

Absolute and relative frequencies for treatment-emergent AEs by primary system organ class – Entire treatment period (Safety set)

Primary system organ class	AIN457 150 mg - AIN457 300 mg s.c. N=15 n (%)	AIN457 300 mg - AIN457 300 mg s.c. N=6 n (%)	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14 n (%)	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8 n (%)
Any primary system organ class	10 (66.7)	5 (83.3)	12 (85.7)	6 (75.0)
Infections and infestations	8 (53.3)	3 (50.0)	6 (42.9)	4 (50.0)
Injury, poisoning and procedural complications	2 (13.3)	1 (16.7)	2 (14.3)	1 (12.5)
Musculoskeletal and connective tissue disorders	1 (6.7)	2 (33.3)	0 (0.0)	1 (12.5)
Respiratory, thoracic and mediastinal disorders	2 (13.3)	1 (16.7)	0 (0.0)	1 (12.5)
Skin and subcutaneous tissue disorders	2 (13.3)	1 (16.7)	6 (42.9)	2 (25.0)
Vascular disorders	2 (13.3)	1 (16.7)	1 (7.1)	0 (0.0)
Gastrointestinal disorders	0 (0.0)	2 (33.3)	1 (7.1)	1 (12.5)
General disorders and administration site conditions	2 (13.3)	0 (0.0)	2 (14.3)	0 (0.0)
Immune system disorders	2 (13.3)	0 (0.0)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)
Cardiac disorders	1 (6.7)	0 (0.0)	1 (7.1)	0 (0.0)
Eye disorders	1 (6.7)	0 (0.0)	2 (14.3)	0 (0.0)
Investigations	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (6.7)	0 (0.0)	1 (7.1)	0 (0.0)
Nervous system disorders	1 (6.7)	0 (0.0)	2 (14.3)	1 (12.5)
Renal and urinary disorders	0 (0.0)	1 (16.7)	0 (0.0)	1 (12.5)
Reproductive system and breast disorders	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Primary system organ class	n (%)	n (%)	n (%)	n (%)
Blood and lymphatic system disorders	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)

	AIN457 300 mg s.c. N=21 N (%)	AIN457 10 mg /kg i.v. N=22 N (%)
Primary system organ class		
Any primary system organ class	15 (71.4)	18 (81.8)
Infections and infestations	11 (52.4)	10 (45.5)
Injury, poisoning and procedural complications	3 (14.3)	3 (13.6)
Musculoskeletal and connective tissue disorders	3 (14.3)	1 (4.5)
Respiratory, thoracic and mediastinal disorders	3 (14.3)	1 (4.5)
Skin and subcutaneous tissue disorders	3 (14.3)	8 (36.4)
Vascular disorders	3 (14.3)	1 (4.5)
Gastrointestinal disorders	2 (9.5)	2 (9.1)
General disorders and administration site conditions	2 (9.5)	2 (9.1)
Immune system disorders	2 (9.5)	0 (0.0)
Metabolism and nutrition disorders	2 (9.5)	0 (0.0)
Cardiac disorders	1 (4.8)	1 (4.5)
Eye disorders	1 (4.8)	2 (9.1)
Investigations	1 (4.8)	0 (0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (4.8)	1 (4.5)
Nervous system disorders	1 (4.8)	3 (13.6)
Renal and urinary disorders	1 (4.8)	1 (4.5)
Reproductive system and breast disorders	1 (4.8)	0 (0.0)
Blood and lymphatic system disorders	0 (0.0)	1 (4.5)

Primary system organ classes are sorted in descending order of frequency in secukinumab 300 mg s.c. group

Absolute and relative frequencies for most frequent ($\geq 7\%$ in any treatment group) treatment-emergent AEs by preferred term – Entire treatment period (Safety set)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Preferred term	n (%)	n (%)	n (%)	n (%)
Any preferred term	10 (66.7)	5 (83.3)	12 (85.7)	6 (75.0)
Nasopharyngitis	3 (20.0)	1 (16.7)	3 (21.4)	2 (25.0)
Pharyngitis	1 (6.7)	1 (16.7)	1 (7.1)	0 (0.0)
Dehydration	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Diarrhoea	0 (0.0)	1 (16.7)	0 (0.0)	1 (12.5)
Excoriation	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Flushing	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Gingivitis ulcerative	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Haemoglobin decreased	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Herpes zoster	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Hypertension	1 (6.7)	0 (0.0)	1 (7.1)	0 (0.0)
Injection site pain	1 (6.7)	0 (0.0)	1 (7.1)	0 (0.0)
Muscle spasms	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Myalgia	0 (0.0)	1 (16.7)	0 (0.0)	1 (12.5)
Nephrolithiasis	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Oropharyngeal pain	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Pharyngeal oedema	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Pharyngitis streptococcal	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Skin lesion	0 (0.0)	1 (16.7)	1 (7.1)	0 (0.0)
Thrombophlebitis	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Toothache	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Type 2 diabetes mellitus	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Upper respiratory tract infection	1 (6.7)	0 (0.0)	1 (7.1)	1 (12.5)
Weight decreased	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Alopecia	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Atrioventricular block first degree	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Back pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Bronchitis bacterial	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Chest pain	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Conjunctivitis allergic	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Dermatitis allergic	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Dermatitis contact	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)

	AIN457 150 mg - AIN457 300 mg s.c. N=15	AIN457 300 mg - AIN457 300 mg s.c. N=6	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8
Preferred term	n (%)	n (%)	n (%)	n (%)
Ear infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Ecchymosis	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Enuresis	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Eyelids pruritus	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Fall	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Folliculitis	0 (0.0)	0 (0.0)	2 (14.3)	1 (12.5)
Headache	0 (0.0)	0 (0.0)	2 (14.3)	0 (0.0)
Ileal ulcer	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Intertrigo	0 (0.0)	0 (0.0)	1 (7.1)	1 (12.5)
Lymphadenopathy	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Pruritus generalised	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Pyogenic granuloma	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Rhinitis	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Sciatica	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Seborrhoeic dermatitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Sinusitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Skin fissures	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Tinea pedis	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Tooth fracture	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)
Upper limb fracture	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)

	AIN457 300 mg s.c. N=21	AIN457 10 mg /kg i.v. N=22
Preferred term	n (%)	n (%)
Any preferred term	15 (71.4)	18 (81.8)
Nasopharyngitis	4 (19.0)	5 (22.7)
Pharyngitis	2 (9.5)	1 (4.5)
Dehydration	1 (4.8)	0 (0.0)
Diarrhoea	1 (4.8)	1 (4.5)
Excoriation	1 (4.8)	0 (0.0)
Flushing	1 (4.8)	0 (0.0)
Gingivitis ulcerative	1 (4.8)	0 (0.0)
Haemoglobin decreased	1 (4.8)	0 (0.0)
Herpes zoster	1 (4.8)	0 (0.0)
Hypertension	1 (4.8)	1 (4.5)
Injection site pain	1 (4.8)	1 (4.5)
Muscle spasms	1 (4.8)	0 (0.0)
Myalgia	1 (4.8)	1 (4.5)

Preferred term	AIN457 300 mg s.c.	AIN457 10 mg /kg i.v.
	N=21 n (%)	N=22 n (%)
Nephrolithiasis	1 (4.8)	0 (0.0)
Oropharyngeal pain	1 (4.8)	0 (0.0)
Pharyngeal oedema	1 (4.8)	0 (0.0)
Pharyngitis streptococcal	1 (4.8)	0 (0.0)
Skin lesion	1 (4.8)	1 (4.5)
Thrombophlebitis	1 (4.8)	0 (0.0)
Toothache	1 (4.8)	0 (0.0)
Type 2 diabetes mellitus	1 (4.8)	0 (0.0)
Upper respiratory tract infection	1 (4.8)	2 (9.1)
Weight decreased	1 (4.8)	0 (0.0)
Alopecia	0 (0.0)	1 (4.5)
Atrioventricular block first degree	0 (0.0)	1 (4.5)
Back pain	0 (0.0)	1 (4.5)
Bronchitis bacterial	0 (0.0)	1 (4.5)
Chest pain	0 (0.0)	1 (4.5)
Conjunctivitis allergic	0 (0.0)	1 (4.5)
Dermatitis allergic	0 (0.0)	1 (4.5)
Dermatitis contact	0 (0.0)	1 (4.5)
Ear infection	0 (0.0)	1 (4.5)
Ecchymosis	0 (0.0)	1 (4.5)
Enuresis	0 (0.0)	1 (4.5)
Epistaxis	0 (0.0)	1 (4.5)
Eyelids pruritus	0 (0.0)	1 (4.5)
Fall	0 (0.0)	1 (4.5)
Folliculitis	0 (0.0)	3 (13.6)
Headache	0 (0.0)	2 (9.1)
Ileal ulcer	0 (0.0)	1 (4.5)
Intertrigo	0 (0.0)	2 (9.1)
Lymphadenopathy	0 (0.0)	1 (4.5)
Pruritus generalised	0 (0.0)	1 (4.5)
Pyogenic granuloma	0 (0.0)	1 (4.5)
Rhinitis	0 (0.0)	1 (4.5)
Sciatica	0 (0.0)	1 (4.5)
Seborrhoeic dermatitis	0 (0.0)	1 (4.5)
Sinusitis	0 (0.0)	1 (4.5)
Skin fissures	0 (0.0)	1 (4.5)
Tinea pedis	0 (0.0)	1 (4.5)
Tooth fracture	0 (0.0)	1 (4.5)
Upper limb fracture	0 (0.0)	1 (4.5)

Primary system organ classes are sorted in descending order of frequency in secukinumab 300 mg s.c. group

Deaths

There were no deaths reported in this study

Serious adverse events

i.v. period

No treatment-emergent serious adverse events were reported during the i.v. period

Entire treatment period

Treatment-emergent SAEs by primary system organ class and preferred term – Entire treatment period (Safety set)						
	AIN457 150 mg - AIN457 300 mg s.c. N=15 n (%)	AIN457 300 mg - AIN457 300 mg s.c. N=6 n (%)	AIN457 150 mg - AIN457 10 mg/kg i.v. N=14 n (%)	AIN457 300 mg - AIN457 10 mg/kg i.v. N=8 n (%)	AIN457 300 mg s.c. N=21 n (%)	AIN457 10 mg /kg i.v. N=22 n (%)
Subjects with any AE(s)	10 (66.7)	5 (83.3)	12 (85.7)	6 (75.0)	15 (71.4)	18 (81.8)
Subjects with serious or other significant events						
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Non-fatal SAE(s)	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	1 (4.5)
Discontinued study treatment due to any AE(s)	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	1 (4.5)

Treatment-free follow up period

There were no deaths, SAEs, or discontinuations due to AEs that occurred during the follow-up period among the 5 patients who entered the follow-up period.

One AE of worsening inflammatory psoriasis was reported by a patient in the secukinumab 300 mg/300 mg s.c. group.

Conclusion

In this trial, uptitration with an i.v. loading dose regimen was not shown to be statistically superior to s.c. uptitration or continued s.c. dosing in achieving PASI 75 and IGA mod 2011 0 or 1 response in initial partial responders to secukinumab. However, the observed response rates in this study, which were directly related to increased levels of secukinumab exposure, suggest that higher exposure to secukinumab provides better responses for patients. No new safety signal was identified during this study.

Date of Clinical Trial Report

Week 40 CS: 09-Oct-2013

Week 48 Follow up Period CSR: 23-Apr-2014

Date Inclusion on Novartis Clinical Trial Results Database

15-April-2014

Date of Latest Update

02-December-2014

Reason for Update

Secondary objectives and secondary efficacy outcome measures' tables were added.